Trospium chloride improves overactive bladder symptoms: A multicenter phase III trial

Journal of Urology

Volumn 171, Issue 6 I, 2004, Pages 2311-2315

  Zinner, Norman ^a,g   Gittelman, Marc ^c   Harris, Richard ^d   Susset, Jacques ^e   Kanellos, Angelo ^f   Auerbach, Stephen ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b California Professional Research   (United States)

^c South Florida Medical Research   (United States)

^d Research Institute   (United States)

^e Multimed Research   (United States)

^f Nevada Urology Associates   (United States)

^g NONE   (United States)

Author keywords

Bladder, neurogenic; Cholinergic antagonists

Indexed keywords

TROSPIUM CHLORIDE;

ABDOMINAL PAIN; ADULT; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HEADACHE; HUMAN; INCONTINENCE IMPACT QUESTIONNAIRE; LETHARGY; MAJOR CLINICAL STUDY; MALE; MICTURITION; MULTICENTER STUDY; OVERACTIVE BLADDER; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SOMNOLENCE; TREATMENT OUTCOME; URGE INCONTINENCE; URINE VOLUME; VISUAL IMPAIRMENT; XEROSTOMIA;

EID: 2442562363     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000127742.73136.0c     Document Type: Article

References (20)

1. Abrams, P., Cardozo, L., Fall, M., Griffiths, D., Rosier, P., Ulmsten, U. et al: The standardisation of terminology of lower urinary tract function: report from the Standardisation Subcommittee of the International Continence Society. Neurourol Urodyn, 21: 167, 2002
2. de Groat, W. C.: A neurologic basis for the overactive bladder. Urology, suppl., 50: 36, 1997
3. Persistency Data. Atlanta, Georgia: NDC Health Corporation, 2000
4. Alloussi, S., Baldauf, J., Derouet, H., Zwergel, U. and Meessen, S.: Effect of trospium chloride, oxybutynin and propiverine on the interaction of acetylcholine with isolated preparations of the human urinary bladder. In: Investigative Urologie IV. Edited by D. Josham, J. W. Thüroff and H. Rübben. Heidelberg: Springer-Verlag, 1991
5. Pietzko, A., Dimpfel, W., Schwantes, U. and Topfmeier, P.: Influences of trospium chloride and oxybutynin on quantitative EEG in healthy volunteers. Eur J Clin Pharmacol, 47: 337, 1994
6. Todorova, A., Vonderheid-Guth, B. and Dimpfel, W.: Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system. J Clin Pharmacol, 41: 636, 2001
7. Herberg, K.-W.: General and traffic safety and the effects of incontinence mediation: new studies on the safety potential of urological anticholinergics. Die Medizinische Welt, 50: 217, 1999
8. Uckert, S., Stief, C. G., Odenthal, K. P., Truss, M. C., Lietz, B. and Jonas, U.: Responses of isolated normal human detrusor muscle to various spasmolytic drugs commonly used in the treatment of the overactive bladder. Arzneimittelforschung, 50: 456, 2000
9. Hofner, K., Oelke, M., Machtens, S. and Grunewald, V.: Trospium chloride - an effective drug in the treatment of overactive bladder and detrusor hyperreflexia. World J Urol, 19: 336, 2001
10. Beckmann-Knopp, S., Rietbrock, S., Weyhenmeyer, R., Bocker, R. H., Beckurts, K. T., Lang, W. et al: Inhibitory effects of trospium chloride on cytochrome P450 enzymes in human liver microsomes. Pharmacol Toxicol, 85: 299, 1999
11. Schladitz-Keil, G., Spahn, H. and Mutschler, E.: Determination of the bioavailability of the quaternary compound trospium chloride in man from urinary excretion data. Arzneimittelforschung, 36: 984, 1986
12. Halaska, M., Ralph, G., Wiedemann, A., Primus, G., Ballering-Bruhl, B., Hofner, K. et al: Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability. World J Urol, 20: 392, 2003
13. Jünemann, K. P. and Al-Shukri, S.: Efficacy and tolerability of trospium chloride and tolterodine in 234 patients with urgesyndrome: a double-blind, placebo-controlled, multicentre clinical trial. Presented at International Continence Society annual meeting, Tampere, August 28, 2000
14. Bowden, A., Colman, S., Sabounjian, L., Sandage, B., Schwiderski, U. and Zayed, H.: Psychometric validation of an urgency severity scale (IUSS) for patients with overactive bladder. Presented at Proceedings of the International Continence Society annual meeting, Florence, Italy, October 5-9, 2003
15. Shumaker, S. A., Wyman, J. F., Uebersax, J. S., McClish, D. and Fantl, J. A.: Health-related quality of life measures for women with urinary incontinence: the Incontinence Impact Questionnaire and the Urogenital Distress Inventory. Continence Program in Women (CPW) Research Group. Qual Life Res, 3:291, 1994
16. Smoger, S. H., Felice, T. L. and Kloecker, G. H.: Urinary incontinence among male veterans receiving care in primary care clinics. Ann Intern Med, 132: 547, 2000
17. Frohlich, G., Bulitta, M. and Strosser, W.: Trospium chloride in patients with detrusor overactivity: meta-analysis of placebo-controlled, randomized, double-blind, multi-center clinical trials on the efficacy and safety of 20 mg trospium chloride twice daily. Int J Clin Pharmacol Ther, 40: 295, 2002
18. Cardozo, L., Chapple, C. R., Toozs-Hobson, P., Grosse-Freese, M., Bulitta, M., Lehmacher, W. et al: Efficacy of trospium chloride in patients with detrusor instability: a placebo-controlled, randomized, double-blind, multicentre clinical trial. BJU Int, 85: 659, 2000
19. Madersbacher, H., Stohrer, M., Richter, R., Burgdorfer, H., Hachen, H. J. and Murtz, G.: Trospium chloride versus oxybutynin: a randomized, double-blind, multicentre trial in the treatment of detrusor hyper-reflexia. Br J Urol, 75: 452, 1995
20. Diefenbach, K., Donath, F., Maurer, A., Bravo, S. Q., Werncke, K.-D., Schwantes, U. et al: Randomised, double-blind study of the effects of oxybutynin, tolterodine, trospium chloride and placebo on sleep in healthy young volunteers. Clin Drug Invest, 23: 395, 2003